OncoMatch/Clinical Trials/NCT06348108
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Is NCT06348108 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Talquetamab and Iberdomide for multiple myeloma.
Treatment: Talquetamab · Iberdomide · Dexamethasone — This phase I trial will evaluate the safety, side effects, and best dose of talquetamab in combination with iberdomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). There is currently a significant unmet need for patients with relapsed or refractory multiple myeloma (RRMM) who are triple class refractory and have been exposed to B-cell maturation antibody (BCMA) targeted therapy. These patients currently have limited treatment options and poor survival. Talquetamab is an FDA approved drug that can bring T-cells to the myeloma cell, resulting in myeloma cell death. Iberdomide is an investigational drug and works by targeting and destroying proteins that help myeloma cancer cells to survive. Dexamethasone is a corticosteroid, is similar to a natural hormone produced by the adrenal glands to reduce inflammation (swelling, heat, redness, and pain) and is used to in helping to treat certain types of cancer including myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
TCE RRMM (including a proteasome inhibitor (PI) (≥ 2 cycles or 2 months of treatment)
Must have received: immunomodulatory drug
TCE RRMM (including...an immunomodulatory drug (IMiD) (≥ 2 cycles or 2 months of treatment)
Must have received: CD38 antibody
TCE RRMM (including...a CD38 antibody (≥ 2 cycles or 2 months of treatment)
Cannot have received: GPRC5D targeted bispecific antibody
Has had any prior GPRC5D targeted bispecific antibody therapy
Cannot have received: GPRC5D CAR-T therapy
Has had any prior...GPRC5D CAR-T therapy
Cannot have received: Iberdomide (Iberdomide)
has had previous treatment with Iber
Cannot have received: allogeneic stem cell transplant
Exception: within 6 months before the first dose of study treatment; if > 6 months from alloSCT must be off all immunosuppression and without evidence of active graft-versus-host disease (GVHD)
Has received treatment with allogeneic stem cell transplant within 6 months before the first dose of study treatment and if > 6 months from allogeneic stem cell transplantation (alloSCT) must be off all immunosuppression and without evidence of active graft-versus-host disease (GVHD).
Lab requirements
Blood counts
ANC ≥ 1.0 x 10^9/L (no myeloid growth factors within 7 days (14 days for extended 1/2-life products)); Hemoglobin ≥ 8 g/dL (transfusions permitted if disease-related); Platelet count ≥ 100 x 10^9/L (dose expansion: ≥ 75 x 10^9/L) with no platelet transfusions during the 7 days before first dose
Kidney function
Calculated creatinine clearance > 30 mL/min
Liver function
Serum bilirubin ≤ 1.5 mg/dL, excluding Gilbert's; AST and ALT ≤ 2.5 × institutional upper limit normal (ULN)
Has adequate baseline organ function, as demonstrated by... Calculated creatinine clearance > 30 mL/min... Serum bilirubin ≤ 1.5 mg/dL, excluding Gilbert's. AST and ALT ≤ 2.5 × institutional upper limit normal (ULN)... Has adequate baseline hematologic function, as demonstrated by... ANC ≥ 1.0 x 10^9/L... Hemoglobin ≥ 8 g/dL... Platelet count ≥ 100 x 10^9/L (dose expansion: ≥ 75 x 10^9/L) with no platelet transfusions during the 7 days before first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Calfornia, San Francisco · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify